Picture loading failed.

Pre-Made Uliledlimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Uliledlimab is a CD73 (5-Nucleotidase) targeting humanised monoclonal antibody, being developed I-Mab Biopharma, for the treatment of various cancers, including solid tumours.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-599-1mg 1mg 3090
GMP-Bios-ab-599-10mg 10mg 21890
GMP-Bios-ab-599-100mg 100mg 148000
GMP-Bios-ab-599-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Uliledlimab biosimilar, Whole mAb, Anti-NT5E/CD73 Antibody: Anti-NT/eN/NT5/NTE/eNT/E5NT/CALJA therapeutic antibody
INN Name Uliledlimab
TargetCD73
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesTRACON Pharmaceuticals;I-Mab Biopharma
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna